Статті в журналах з теми "Programmed cell death ligand 1"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Programmed cell death ligand 1".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Liu, Qiang, and Chun-Sheng Li. "Programmed Cell Death-1/Programmed Death-ligand 1 Pathway." Chinese Medical Journal 130, no. 8 (April 2017): 986–92. http://dx.doi.org/10.4103/0366-6999.204113.
Повний текст джерелаJaafar, Jaafar, Eugenio Fernandez, Heba Alwan, and Jacques Philippe. "Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism." Endocrine Connections 7, no. 5 (May 2018): R196—R211. http://dx.doi.org/10.1530/ec-18-0079.
Повний текст джерелаVerhoeff, Sarah R., Michel M. van den Heuvel, Carla M. L. van Herpen, Berber Piet, Erik H. J. G. Aarntzen, and Sandra Heskamp. "Programmed Cell Death-1/Ligand-1 PET Imaging." PET Clinics 15, no. 1 (January 2020): 35–43. http://dx.doi.org/10.1016/j.cpet.2019.08.008.
Повний текст джерелаFang, Xiao-Na, and Li-Wu Fu. "Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy." Recent Patents on Anti-Cancer Drug Discovery 11, no. 2 (April 15, 2016): 141–51. http://dx.doi.org/10.2174/1574892811666160226150506.
Повний текст джерелаYu, Wesley Y., Timothy G. Berger, Jeffrey P. North, Zoltan Laszik, and Jarish N. Cohen. "Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts." Journal of the American Academy of Dermatology 81, no. 5 (November 2019): 1127–33. http://dx.doi.org/10.1016/j.jaad.2019.02.063.
Повний текст джерелаTamura, Akihiro, Makiko Yoshida, Nobuyuki Yamamoto, Nanako Nino, Naoko Nakatani, Takayuki Ichikawa, Sayaka Nakamura, et al. "Programmed Death-1 and Programmed Death-Ligand 1 Expression Patterns in Pediatric Lymphoma." Blood 132, Supplement 1 (November 29, 2018): 5316. http://dx.doi.org/10.1182/blood-2018-99-110732.
Повний текст джерелаZhang, Ni, Jingyao Tu, Xue Wang, and Qian Chu. "Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action." Immunotherapy 11, no. 5 (April 2019): 429–41. http://dx.doi.org/10.2217/imt-2018-0110.
Повний текст джерелаZhao, Wanying, Yuanzheng Liang, and Liang Wang. "Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies." Aging Pathobiology and Therapeutics 3, no. 4 (December 31, 2021): 84–94. http://dx.doi.org/10.31491/apt.2021.12.071.
Повний текст джерелаWang, Tianyu, Xiaoxing Wu, Changying Guo, Kuojun Zhang, Jinyi Xu, Zheng Li, and Sheng Jiang. "Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway." Journal of Medicinal Chemistry 62, no. 4 (September 24, 2018): 1715–30. http://dx.doi.org/10.1021/acs.jmedchem.8b00990.
Повний текст джерелаShen, Jacson K., Gregory M. Cote, Edwin Choy, Pei Yang, David Harmon, Joseph Schwab, G. Petur Nielsen, et al. "Programmed Cell Death Ligand 1 Expression in Osteosarcoma." Cancer Immunology Research 2, no. 7 (April 21, 2014): 690–98. http://dx.doi.org/10.1158/2326-6066.cir-13-0224.
Повний текст джерелаWolkow, Natalie, Frederick A. Jakobiec, Amir H. Afrogheh, Ralph C. Eagle, Sara I. Pai, and William C. Faquin. "Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications." American Journal of Ophthalmology 200 (April 2019): 226–41. http://dx.doi.org/10.1016/j.ajo.2018.12.020.
Повний текст джерелаNiedźwiedzka-Rystwej, Paulina, Adam Majchrzak, Bogusz Aksak-Wąs, Karol Serwin, Zenon Czajkowski, Ewelina Grywalska, Izabela Korona-Głowniak, Jacek Roliński, and Miłosz Parczewski. "Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity." Cells 11, no. 12 (June 20, 2022): 1978. http://dx.doi.org/10.3390/cells11121978.
Повний текст джерелаZhang, Jingyi, Kexin Tan, Xuejiao Jiang, Shuyue Zheng, Jia Li, Chongxiang Xue, Xu Zhang, and Huijuan Cui. "The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors." Medicine 100, no. 28 (July 16, 2021): e26649. http://dx.doi.org/10.1097/md.0000000000026649.
Повний текст джерелаDeng, Tuo, and Guohua Zeng. "Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer." JAMA Oncology 6, no. 7 (July 1, 2020): 1113. http://dx.doi.org/10.1001/jamaoncol.2020.0625.
Повний текст джерелаBomze, David, Daniel Azoulay, and Tomer Meirson. "Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer." JAMA Oncology 6, no. 7 (July 1, 2020): 1114. http://dx.doi.org/10.1001/jamaoncol.2020.0628.
Повний текст джерелаWang, Tao, Shiowjen Lee, and Gerald M. Feldman. "Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer." JAMA Oncology 6, no. 7 (July 1, 2020): 1115. http://dx.doi.org/10.1001/jamaoncol.2020.0631.
Повний текст джерелаGhiorghiu, Serban, Pralay Mukhopadhyay, and Cristian Massacesi. "Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer." JAMA Oncology 6, no. 7 (July 1, 2020): 1115. http://dx.doi.org/10.1001/jamaoncol.2020.0637.
Повний текст джерелаSun, Lejia, Huayu Yang, and Yilei Mao. "Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids." Annals of Translational Medicine 7, S8 (December 2019): S287. http://dx.doi.org/10.21037/atm.2019.11.76.
Повний текст джерелаNaidoo, Jarushka, Xuan Wang, Kaitlin M. Woo, Tunc Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E. Chaft, et al. "Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy." Journal of Clinical Oncology 35, no. 7 (March 1, 2017): 709–17. http://dx.doi.org/10.1200/jco.2016.68.2005.
Повний текст джерелаFakhri, Ghina, Reem Akel, Ibrahim Khalifeh, Hassan Chami, Adel Hajj Ali, Majd Al Assaad, Haneen Atwi, Humam Kadara, and Arafat Tfayli. "Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon." SAGE Open Medicine 9 (January 2021): 205031212110437. http://dx.doi.org/10.1177/20503121211043709.
Повний текст джерелаKim, J., J. H. Choi, J. Kong, W. Yang, H. Cho, D. B. Chay, and J. H. Kim. "Prognostic implication of programmed cell death 1 protein and programmed cell death 1 ligand 1 expression in endometrial cancer." Gynecologic Oncology 149 (June 2018): 47. http://dx.doi.org/10.1016/j.ygyno.2018.04.100.
Повний текст джерелаXu, Dongmei, Hongmei Liu, Meiyi Xiang, Alei Feng, Mei Tian, Donghua Li, Yantao Mao, Li Zhang, Shuisheng Zhang, and Yuan Tian. "The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients." Medicine 99, no. 41 (October 9, 2020): e22567. http://dx.doi.org/10.1097/md.0000000000022567.
Повний текст джерелаHu-Lieskovan, Siwen, and Antoni Ribas. "New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone." Cancer Journal 23, no. 1 (2017): 10–22. http://dx.doi.org/10.1097/ppo.0000000000000246.
Повний текст джерелаQin, Mingze, Qi Cao, Xia Wu, Chunyang Liu, Shuaishuai Zheng, Hongbo Xie, Ye Tian, et al. "Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold." European Journal of Medicinal Chemistry 186 (January 2020): 111856. http://dx.doi.org/10.1016/j.ejmech.2019.111856.
Повний текст джерелаWang, Zhijie, Zhengyi Zhao, and Jie Wang. "Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer—Reply." JAMA Oncology 6, no. 7 (July 1, 2020): 1116. http://dx.doi.org/10.1001/jamaoncol.2020.0646.
Повний текст джерелаLondon, Nyall, Justin Bishop, Lisa Rooper, Janis Taube, Masaru Ishii, and Gary Gallia. "Expression of Programmed Cell Death-Ligand 1 in Esthesioneuroblastoma." Journal of Neurological Surgery Part B: Skull Base 79, S 01 (February 2018): S1—S188. http://dx.doi.org/10.1055/s-0038-1633448.
Повний текст джерелаZhang, Guo-Qiang, Wei-Jun Wei, Hong-Jun Song, Zhen-Kui Sun, Chen-Tian Shen, Xin-Yun Zhang, Xiao-Yue Chen, Zhong-Ling Qiu, and Quan-Yong Luo. "PROGRAMMED CELL DEATH–LIGAND 1 OVEREXPRESSION IN THYROID CANCER." Endocrine Practice 25, no. 3 (March 2019): 279–86. http://dx.doi.org/10.4158/ep-2018-0342.
Повний текст джерелаWakeley, Michelle E., Monique E. De Paepe, Chun-Shiang Chung, and Alfred Ayala. "Programmed Cell Death Ligand 1 Protects Against Death in Neonatal Sepsis." Journal of the American College of Surgeons 229, no. 4 (October 2019): S214. http://dx.doi.org/10.1016/j.jamcollsurg.2019.08.467.
Повний текст джерелаKawashita, Seiji, Koichi Aoyagi, Hiroshi Yamanaka, Rie Hantani, Shiori Naruoka, Atsuo Tanimoto, Yuji Hori, et al. "Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction." Bioorganic & Medicinal Chemistry Letters 29, no. 17 (September 2019): 2464–67. http://dx.doi.org/10.1016/j.bmcl.2019.07.027.
Повний текст джерелаChang, Katherine, Catherine Svabek, Cristina Vazquez-Guillamet, Bryan Sato, David Rasche, Strother Wilson, Paul Robbins, et al. "Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis." Critical Care 18, no. 1 (2014): R3. http://dx.doi.org/10.1186/cc13176.
Повний текст джерелаJo, Jae-Cheol, Misung Kim, Yunsuk Choi, Hyun-Jung Kim, Ji Eun Kim, Seoung Wan Chae, Hawk Kim, and Hee Jeong Cha. "Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type." Annals of Hematology 96, no. 1 (October 3, 2016): 25–31. http://dx.doi.org/10.1007/s00277-016-2818-4.
Повний текст джерелаJo, Jae-Cheol, Yunsuk Choi, Hee Jeong Cha, Eun Hee Lee, Eun Kyoung Kang, and Hawk Kim. "Expression of Programmed Cell Death 1 and Programmed Cell Death Ligand 1 in Extranodal NK/T-Cell Lymphoma, Nasal Type." Blood 126, no. 23 (December 3, 2015): 1461. http://dx.doi.org/10.1182/blood.v126.23.1461.1461.
Повний текст джерелаLee, Joo Sang, and Eytan Ruppin. "Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1." JAMA Oncology 5, no. 11 (November 1, 2019): 1614. http://dx.doi.org/10.1001/jamaoncol.2019.2311.
Повний текст джерелаGuan, Xiuwen, Haijuan Wang, Fei Ma, Haili Qian, Zongbi Yi, and Binghe Xu. "The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma." Medicine 95, no. 11 (March 2016): e3134. http://dx.doi.org/10.1097/md.0000000000003134.
Повний текст джерелаZhao, Bin, Hong Zhao, and Jiaxin Zhao. "Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer." Therapeutic Advances in Medical Oncology 12 (January 2020): 175883591989575. http://dx.doi.org/10.1177/1758835919895753.
Повний текст джерелаLi, Mingkai, Linlin Huang, Xiuhong Ren, Lixia Liu, Qinghong Shi, Ling Liu, Xiao Wang, Yuan Tian, Lili Yu, and Fuli Mi. "The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients." Medicine 99, no. 42 (October 16, 2020): e22555. http://dx.doi.org/10.1097/md.0000000000022555.
Повний текст джерелаDuan, Jianchun, Longgang Cui, Xiaochen Zhao, Hua Bai, Shangli Cai, Guoqiang Wang, Zhengyi Zhao, et al. "Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer." JAMA Oncology 6, no. 3 (March 1, 2020): 375. http://dx.doi.org/10.1001/jamaoncol.2019.5367.
Повний текст джерелаGreaves, Paul, and John G. Gribben. "The role of B7 family molecules in hematologic malignancy." Blood 121, no. 5 (January 31, 2013): 734–44. http://dx.doi.org/10.1182/blood-2012-10-385591.
Повний текст джерелаKim, Jong Hoon, Young Joon Choi, Byung Ha Lee, Mi-Young Song, Chae Yeon Ban, Jihye Kim, Junsik Park, et al. "Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1–high T cells." Journal of Allergy and Clinical Immunology 137, no. 5 (May 2016): 1466–76. http://dx.doi.org/10.1016/j.jaci.2015.11.021.
Повний текст джерелаTay, Woan Ting, Yi-Hsien Fang, Suet Theng Beh, Yen-Wen Liu, Ling-Wei Hsu, Chia-Jui Yen, and Ping-Yen Liu. "Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro." International Journal of Molecular Sciences 21, no. 7 (March 31, 2020): 2399. http://dx.doi.org/10.3390/ijms21072399.
Повний текст джерелаYang, Lu-Lu, and Yi-Long Wu. "Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies." Lung Cancer Management 3, no. 2 (April 2014): 175–90. http://dx.doi.org/10.2217/lmt.13.80.
Повний текст джерелаMuszak, Damian, Ewa Surmiak, Jacek Plewka, Katarzyna Magiera-Mularz, Justyna Kocik-Krol, Bogdan Musielak, Dominik Sala, et al. "Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction." Journal of Medicinal Chemistry 64, no. 15 (July 27, 2021): 11614–36. http://dx.doi.org/10.1021/acs.jmedchem.1c00957.
Повний текст джерелаFeng, Jamie, and Natasha B. Leighl. "There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor." Journal of Thoracic Oncology 17, no. 10 (October 2022): 1175–77. http://dx.doi.org/10.1016/j.jtho.2022.07.1150.
Повний текст джерелаGeisler, Benjamin P., Leesa L. Pridham, M. Cecilia Monge B., Tali M. Johnson, Jonathan Karnon, and Elad Sharon. "Cost-effectiveness of programmed cell death protein 1/programmed death-ligand 1 inhibitors (aPD1/aPDL1) varies widely." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e18351-e18351. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18351.
Повний текст джерелаAlmahmoud, Suliman, and Haizhen A. Zhong. "Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors." International Journal of Molecular Sciences 20, no. 18 (September 19, 2019): 4654. http://dx.doi.org/10.3390/ijms20184654.
Повний текст джерелаKojima, Kensuke, Tetsuki Sakamoto, Takahiko Kasai, Shinji Atagi, and Hyungeun Yoon. "A quantitative evaluation of the histological type dependence of the programmed death-ligand 1 expression in non-small cell lung cancer including various adenocarcinoma subtypes: a cross-sectional study." Japanese Journal of Clinical Oncology 52, no. 3 (December 29, 2021): 281–85. http://dx.doi.org/10.1093/jjco/hyab202.
Повний текст джерелаXia, Yunfei, Zilu Huang, Shuohan Zheng, Shirong Ding, Yinghong Wei, Chen Chen, Xing Liu, and He Li. "Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials." Journal of Cancer Research and Therapeutics 17, no. 3 (2021): 676. http://dx.doi.org/10.4103/jcrt.jcrt_1606_20.
Повний текст джерелаDesforges, Ploa, Khashayar Esfahani, and Nathaniel Bouganim. "Programmed Cell Death Ligand 1–Induced Coma From Diffuse Cerebritis." Journal of Oncology Practice 14, no. 2 (February 2018): 134–35. http://dx.doi.org/10.1200/jop.2017.024992.
Повний текст джерелаChandrasekaran, Deepika, Sandhya Sundaram, Kadhiresan N, and Padmavathi R. "Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma." Asian Pacific Journal of Cancer Prevention 20, no. 10 (October 1, 2019): 2951–57. http://dx.doi.org/10.31557/apjcp.2019.20.10.2951.
Повний текст джерелаKerr, Keith M., and Fred R. Hirsch. "Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?" Archives of Pathology & Laboratory Medicine 140, no. 4 (January 12, 2016): 326–31. http://dx.doi.org/10.5858/arpa.2015-0522-sa.
Повний текст джерела